Selling, General, and Administrative Costs: Rhythm Pharmaceuticals, Inc. vs Geron Corporation

Biotech SG&A Expenses: A Decade of Change

__timestampGeron CorporationRhythm Pharmaceuticals, Inc.
Wednesday, January 1, 2014167580001213000
Thursday, January 1, 2015177930003425000
Friday, January 1, 2016187610006311000
Sunday, January 1, 2017192870009518000
Monday, January 1, 20181870700028080000
Tuesday, January 1, 20192089300036550000
Wednesday, January 1, 20202567800046125000
Friday, January 1, 20212966500068486000
Saturday, January 1, 20224362800092032000
Sunday, January 1, 202369135000117532000
Loading chart...

Unleashing insights

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Rhythm Pharmaceuticals, Inc. and Geron Corporation from 2014 to 2023. Over this period, Rhythm Pharmaceuticals has seen a staggering increase in SG&A expenses, growing nearly 97 times from 2014 to 2023. In contrast, Geron Corporation's expenses have increased by approximately 312% over the same period.

Key Insights

  • Rhythm Pharmaceuticals: Starting with modest expenses in 2014, the company experienced a significant rise, peaking in 2023 with expenses over 11 times higher than in 2018.
  • Geron Corporation: While growth was steadier, the company saw a notable jump in 2023, with expenses more than doubling since 2021.

These trends highlight the dynamic nature of financial management in the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025